Advanced Search

Show simple item record

dc.contributor.authorErsoy Yeşil, Ezgi
dc.contributor.authorYılmaz, Yusuf
dc.contributor.authorYeşil, Atakan
dc.contributor.authorMeşe, Meral
dc.contributor.authorKaya, Eda
dc.contributor.authorArı Bakır, Elif
dc.date.accessioned2023-01-31T15:32:26Z
dc.date.available2023-01-31T15:32:26Z
dc.date.issued2023en_US
dc.identifier.citationErsoy Yeşil, E., Yılmaz, Y., Yeşil, A., Meşe, M., Kaya, E. & Arı Bakır, E. (2023). Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan. Hepatology Forum, 4(1), pp. 14-18. https://doi.org/10.14744/hf.2022.2022.0038en_US
dc.identifier.issn1307-5888
dc.identifier.issn2757-7392
dc.identifier.urihttps://doi.org/10.14744/hf.2022.2022.0038
dc.identifier.urihttps://hdl.handle.net/20.500.13055/383
dc.description.abstractBackground & Aim: Metabolic dysfunction-associated fatty liver disease (MAFLD) is expected to be prevalent among kidney transplant recipients (KTR). In this study, we evaluated the prevalence of MAFLD among KTRs, a data that has not been investigated by any clinical study to date. Matherials and Methods: We included a total of 52 KTRs and 53 age-, sex-, and BMI-matched individuals as control group through a prospective consecutive recruitment. We detected the presence of hepatic steatosis and liver fibrosis using controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) defined by FibroScan. Results: Among the KTRs, 18 (34.6%) had metabolic syndrome. The prevalence of MAFLD among the KTRs and controls was 42.3% and 51.9%, (p=0.375). The CAP and LSM values did not differ significantly between the KTRs and controls (p=0.222 and p=0.119). Among the KTRs, patients with MAFLD had significantly higher age, BMI, waist circumference, LDL, and total cholesterol levels (p<0.001, p=0.011, p=0.033, p=0.022, and p=0.029, respectively). In multivariable analysis, age was the only independent factor for MAFLD among the KTRs (OR: 1.120, CI 95%: 1.039-1.208). Conclusion: MAFLD among KTRs did not show a significantly higher prevalence compared to the normal population. Further clinical studies with larger populations are needed.en_US
dc.language.isoengen_US
dc.publisherKare Publishingen_US
dc.relation.ispartofHepatology Forumen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectFibroscanen_US
dc.subjectKidney Transplant Recipientsen_US
dc.subjectMaflden_US
dc.titlePrevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScanen_US
dc.typearticleen_US
dc.authorid0000-0002-6937-1470en_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.contributor.institutionauthorYeşil, Atakan
dc.identifier.doi10.14744/hf.2022.2022.0038en_US
dc.identifier.volume4en_US
dc.identifier.issue1en_US
dc.identifier.startpage14en_US
dc.identifier.endpage18en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.wosauthoridDZI-8159-2022en_US
dc.scopusauthorid54403988500en_US
dc.description.wospublicationidWOS:000923480400004en_US
dc.description.scopuspublicationid2-s2.0-85164338674en_US
dc.description.pmidPMID: 36843889en_US
dc.relation.indexESCI - Emerging Sources Citation Indexen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record